https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-10-01 / Expert Opin Biol Ther 2005 Oct;5(10):1303-15
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-10-01 / Expert Opin Biol Ther 2005 Oct;5(10):1303-152005-10-01 00:00:002019-02-15 08:44:45Natural killer-dendritic cell cross-talk in cancer immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-09-27 / Cancer Immunol Immunother 2006 Jul;55(7):819-29
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-09-27 / Cancer Immunol Immunother 2006 Jul;55(7):819-292005-09-27 00:00:002005-09-27 00:00:00Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-09-01 / J. Immunother. 2005 Sep-Oct;28(5):496-504
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-09-01 / J. Immunother. 2005 Sep-Oct;28(5):496-5042005-09-01 00:00:002020-01-08 10:10:20Vaccination of advanced hepatocellular carcinoma patients with tumor lysate-pulsed dendritic cells: a clinical trial
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-09-01 / Leukemia 2005 Sep;19(9):1621-7
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-09-01 / Leukemia 2005 Sep;19(9):1621-72005-09-01 00:00:002019-02-15 08:45:56Allogeneic dendritic cells pulsed with tumor lysates or apoptotic bodies as immunotherapy for patients with early-stage B-cell chronic lymphocytic leukemia
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-08-23 / Blood 2005 Dec;106(13):4225-33
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-08-23 / Blood 2005 Dec;106(13):4225-332005-08-23 00:00:002019-02-15 08:44:44Immunomodulatory dendritic cells require autologous serum to circumvent nonspecific immunosuppressive activity in vivo
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-08-01 / Clin. Cancer Res. 2005 Aug;11(15):5515-25
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-08-01 / Clin. Cancer Res. 2005 Aug;11(15):5515-252005-08-01 00:00:002019-02-15 08:46:55Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-06-02 / Blood 2005 Oct;106(7):2252-8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-06-02 / Blood 2005 Oct;106(7):2252-82005-06-02 00:00:002019-02-15 08:44:46Natural-killer cells and dendritic cells: „l’union fait la force“
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-06-01 / Clin. Cancer Res. 2005 Jun;11(11):4160-7
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-06-01 / Clin. Cancer Res. 2005 Jun;11(11):4160-72005-06-01 00:00:002019-02-15 08:46:56Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-05-11 / Cancer Immunol. Immunother. 2006 Mar;55(3):329-38
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-05-11 / Cancer Immunol. Immunother. 2006 Mar;55(3):329-382005-05-11 00:00:002005-05-11 00:00:00Chaperone-rich cell lysates, immune activation and tumor vaccination
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-04-28 / Cancer Immunol. Immunother. 2006 Mar;55(3):292-8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-04-28 / Cancer Immunol. Immunother. 2006 Mar;55(3):292-82005-04-28 00:00:002019-02-15 08:48:23Emerging evidence indicates that physiologically relevant thermal stress regulates dendritic cell function
